Ceragem 'Master V7' Surpasses 20,000 Units in Contracts
100 Days Since April Launch
Reliability and Expertise in Medical Devices Prove Effective
Ceragem announced on the 27th that its new spinal medical device, the 'Master V7 Meditech,' surpassed 20,000 units in contracts within approximately 100 days of its launch. When converted to sales, this amounts to about 110 billion KRW.
The Master V7 Meditech is a product that embodies Ceragem's medical device technology. It features vertical traction massage using gravity and focused heat therapy applied along the spine line, the center of the human body. It has been certified by the Ministry of Food and Drug Safety for five usage purposes: ▲treatment of cervical and lumbar disc herniation ▲treatment of degenerative stenosis ▲relief of muscle pain ▲improvement of blood circulation ▲treatment of menstrual pain.
Ceragem cited the product's efficacy and high consumer trust in its professionalism as reasons for the Master V7 Meditech's success. In fact, a survey conducted last month with 1,893 customers who used the spinal medical device showed that 81.1% responded that they "felt it helped improve their health." Additionally, 60% of customers said they would "actively recommend it to acquaintances."
Hot Picks Today
"Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- "Striking Will Lead to Regret": Hyundai-Kia Employees Speak Out... Uneasy Stares Toward Samsung Union
- Man in His 50s Arrested for Confining Girlfriend in Car After She Announced Breakup
- Assaulted by Elementary Student During Class... No Protection Due to 'Instructor' Status
- "If You Booked This Month, You Almost Lost Out... Why You Should Wait Until 'This Day' Before Paying for Flight Tickets"
A Ceragem representative stated, "Despite the challenging home appliance market due to factors such as high interest rates and inflation, the Master V7 continues to receive steady positive responses based on solid customer trust. We will establish ourselves as a brand consistently loved by consumers through R&D investments in clinical and medical science research and diversification of experience channels."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.